Nurix Therapeutics, Inc.: Form 10-Q for the period ended Aug 31, 2022
Filed with the SEC on Oct 6, 2022 and accepted by EDGAR at Oct 6, 2022, 16:28 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-06-01 to 2022-08-31 | $10.8m | us-gaap:Revenues |
| Revenue | 9 months2021-12-01 to 2022-08-31 | $31.8m | us-gaap:Revenues |
| Research and development | 3 months2022-06-01 to 2022-08-31 | $47.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-12-01 to 2022-08-31 | $138.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-06-01 to 2022-08-31 | −$46.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-12-01 to 2022-08-31 | −$135.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-06-01 to 2022-08-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2021-12-01 to 2022-08-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-06-01 to 2022-08-31 | −$45.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-12-01 to 2022-08-31 | −$133.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-06-01 to 2022-08-31 | −$0.90 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-12-01 to 2022-08-31 | −$2.85 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-06-01 to 2022-08-31 | −$0.90 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-12-01 to 2022-08-31 | −$2.85 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-06-01 to 2022-08-31 | 50,868,542 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-12-01 to 2022-08-31 | 46,835,776 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-12-01 to 2022-08-31 | −$121.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-12-01 to 2022-08-31 | $9.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-08-31 | $47.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-08-31 | $354.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-08-31 | $459.3m | us-gaap:Assets |
| Current liabilities | At period end2022-08-31 | $67.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-08-31 | $116.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-08-31 | $342.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-22-033709. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.